Assessment of Minimal Residual Disease in Standard-Risk AML

The New England Journal of Medicine
Adam IveyUK National Cancer Research Institute AML Working Group

Abstract

Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of remission. Sensitive detection of a leukemia-specific marker (e.g., a mutation in the gene encoding nucleophosmin [NPM1]) could improve prognostication by identifying submicroscopic disease during remission. We used a reverse-transcriptase quantitative polymerase-chain-reaction assay to detect minimal residual disease in 2569 samples obtained from 346 patients with NPM1-mutated AML who had undergone intensive treatment in the National Cancer Research Institute AML17 trial. We used a custom 51-gene panel to perform targeted sequencing of 223 samples obtained at the time of diagnosis and 49 samples obtained at the time of relapse. Mutations associated with preleukemic clones were tracked by means of digital polymerase chain reaction. Molecular profiling highlighted the complexity of NPM1-mutated AML, with segregation of patients into more than 150 subgroups, thus precluding reliable outcome prediction. The determination of minimal-residual-disease status was more informative. Persistence of NPM1-mutated transcripts in blood was present ...Continue Reading

Associated Clinical Trials

References

Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David GrimwadeAlan K Burnett
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
May 25, 2013·Blood·Jan KrönkeKonstanze Döhner
Feb 20, 2014·Proceedings of the National Academy of Sciences of the United States of America·M Ryan Corces-ZimmermanRavindra Majeti
Nov 6, 2014·British Journal of Haematology·Gro G PløenAnni Aggerholm
May 13, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rosemary E GaleDavid C Linch

❮ Previous
Next ❯

Citations

Jan 21, 2016·The New England Journal of Medicine·Michael J Burke
Apr 5, 2016·Expert Review of Molecular Diagnostics·Michael Boyiadzis, Theresa L Whiteside
Jun 3, 2016·International Journal of Hematology·Takahiro Maeda
Nov 3, 2016·Bone Marrow Transplantation·A M BrunnerY B Chen
Jun 28, 2016·Molecular Diagnosis & Therapy·Karl HaslamKen I Mills
Jul 9, 2016·Blood·Richard Dillon, David Grimwade
Jul 16, 2016·American Journal of Hematology·Elihu Estey
Aug 2, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marlise R LuskinRan Reshef
Aug 4, 2016·Leukemia & Lymphoma·Ivana JeziskovaZdenek Racil
Aug 9, 2016·Leukemia Research·Vinay Prasad, Robert Peter Gale
Aug 11, 2016·The New England Journal of Medicine·Robert K HillsUNKNOWN UK National Cancer Research Institute (NCRI) AML Working Group
Sep 7, 2016·Frontiers in Oncology·Hanae SatoKeisuke Ito
Aug 23, 2016·Biomarkers in Medicine·Bhavana Bhatnagar, Ramiro Garzon
Aug 22, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Matthew P MuléChristopher S Hourigan
Dec 3, 2016·Leukemia·H P Koeffler, G Leong
Feb 1, 2017·American Journal of Hematology·Mark Levis
May 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher S HouriganCatherine Lai
Mar 10, 2017·Expert Opinion on Drug Discovery·Gillian A Horne, Mhairi Copland
Dec 23, 2016·Cold Spring Harbor Perspectives in Medicine·Lorenzo BrunettiMargaret A Goodell
Mar 31, 2017·International Journal of Hematology·Diana HanekampGerrit Jan Schuurhuis
Apr 8, 2017·Leukemia·C S HouriganR B Walter
Jan 23, 2017·Current Treatment Options in Oncology·Pamela J Sung, Selina M Luger
Feb 6, 2017·Leukemia Research·Jay L PatelTodd W Kelley
Dec 9, 2016·Current Opinion in Hematology·Francesco Buccisano, Roland B Walter
Jun 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardGail J Roboz
Jun 28, 2017·British Journal of Haematology·Michael Medinger, Jakob R Passweg
Jun 24, 2017·Leukemia·V I GaidzikUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)
Sep 20, 2017·Journal of Clinical Medicine·Gregory W RoloffLaura W Dillon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.